Table 1

Patients’ characteristics and antibiotics data during the pre-ASP and ASP periods

VariableASP−n (%)ASP+n (%)P value
Median age in months (IQR)26 (93)24 (65)0.485
Gender male150 (62.5)86 (63)
PRISM-III5.68 ± 5.147.4 ± 6.3
Diagnosis
Respiratory system diseases27 (20)31 (24.4)> 0.05
Cardiovascular system diseases12 (9)13 (10.2)
Neurological diseases25 (18.5)16 (12.6)
Surgical disease58 (43)41 (32.3)
Miscellaneous13 (9.5)26 (20.5)
Empirical57 (42)60 (47.4)
Prophylaxis58 (43)55 (43.2)
Therapeutic20 (15)12 (9.4)
Intervention None29 (22.6)
DoseNone11 (8.5)
ChoiceNone15 (11.7)
Duration/stop15 %6 (4.6)
Monitor/interactionNone6 (4.6)
DOT1937651
<2 days8 (6)57 (45)
>5 days87 (64)8 (6)
Patient’s days (PtD)557492
DOT/1000 PtD1937/0.557=3477 651/0.492=1323 <0.0001
DOT-vanco3461740.002
DOT-mero3231540.001
DOT-colis1151000.70
DOT-ceftri5321860.00
Cost in PKR2 212 468929 5680.00
Mortality (%)22 (16.2)20 (15.7)
  • ASP, antibiotic stewardship programme; CVS, cerebrovascular disease; DOT,  days of therapy; PKR, Pakistani Rupee; Pt D, patient days; PRISM, Paediatric Risk of Mortality.